Annual Report Analysis of Listed Vitamin Companies in China
Vitamin industry hot topics in 2014:
On 19 March, 2014, BASF released a statement that its citral production line in Germany plant suffered a fire and had to close down. BASF's total citral capacity accounts for more than 60% of the global capacity, thus the fire leads to the tight supply of citral and has a huge impact on the downstream of vitamin A, fragrance and flavor, vitamin E and other products. Though BASF's citral resumed production in April, domestic supply situation didn't change.
On 11 July, 2014, DSM announced that it had reached an agreement to acquire Aland Nutraceutical Holding, Ltd., a leading producer of vitamin C in China. Through the acquisitions, DSM can further strengthen its status in vitamin C market and expand its domains all over the world of human nutrition and health care, animal nutrition and health care and personal care.
On 29 September, 2014, Zhejiang Hangzhou Xinfu Pharmaceutical Co., Ltd. announced that Hefei Yifan Bio-Pharm Co., Ltd., a subsidiary of Xinfu Pharmaceutical, will merge with Hefei Yifan Pharmaceutical Co., Ltd., another subsidiary of Xinfu Pharmaceutical. After the completion of the merger, Yifan Bio-Pharm will continue to exist while Yifan Pharmaceutical will be dismissed and deregistered.
On 5 Nov., 2014, Guangzhou Lonza (Nansha) Co., Ltd. launched a 15,000 t/a vitamin B3 (niacinamide) and formally put into operation, which further enlarged the production capacity of China's vitamin B3. It's estimated that there is a risk of excess capacity.
Purpose of report:
To clearly describe China's vitamin industry, CCM has collected lots of information in various ways. In this report, development situation of vitamin listed companies has been described in detail, including company profile, financial performance, product mix, market share, and investment opportunity.
What to report:
In this report, the 9 listed vitamin companies have been analyzed exhaustively from the following aspects:
Revenue and net profit of the listed vitamin companies, 2009-2013;
Main product structure of the listed vitamin companies by main business revenue, 2013;
Revenue and gross profit margin of vitamin business of the listed vitamin companies, 2009-2013;
Regional distribution of the listed vitamin companies by main business revenue, 2012 and 2013;
Top 5 customers of the listed vitamin companies by total revenue, 2012 and 2013.
R&D investment of the listed vitamin companies, 2012 and 2013
In the next few years, the vitamin industry in China will continue to be promising. On the whole, it’s worth investing in it.
North China Pharmaceutical Co., Ltd. Zhejiang Medicine Co., Ltd. Zhejiang NHU Company Ltd. Northeast Pharmaceutical Group Co., Ltd. PKU HealthCare Corp., Ltd. Brother Enterprises Holding Co., Ltd. Zhejiang Hangzhou Xinfu Pharmaceutical Co., Ltd. Xiamen Kingdomway Group Company Hubei Guangji Pharmaceutical Co., Ltd.